Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 11/20 | 0.52 |
| ▸ | THRB | P10828 | 11/20 | 0.52 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.40 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.37 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | GPR34 | Q9UPC5 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25528523 | 0.90 | THRA (0.51) | THRATHRBMAOBPLA2G10PLA2G2A | |
| SCHEMBL30574240 | 0.90 | THRA (0.61) | THRATHRBPDE4DPLA2G10PLA2G2A | |
| SCHEMBL23003650 | 0.90 | THRA (0.61) | THRATHRBPDE4DPLA2G10PLA2G2A | |
| SCHEMBL25528706 | 0.90 | THRA (0.57) | THRATHRBPLA2G10PLA2G2A | |
| SCHEMBL25528534 | 0.89 | THRA (0.50) | THRATHRBPLA2G10PLA2G2A | |
| SCHEMBL25528533 | 0.89 | THRA (0.51) | THRATHRBMAOBPLA2G10PLA2G2A | |
| SCHEMBL25528524 | 0.89 | THRA (0.51) | THRATHRBPIM1PLA2G10PLA2G2A | |
| SCHEMBL25528539 | 0.89 | THRA (0.50) | THRATHRBMAOBMAOA | |
| SCHEMBL23003714 | 0.89 | THRA (0.50) | THRATHRBPDE4DMAOBMAOA | |
| SCHEMBL23003750 | 0.89 | THRA (0.50) | THRATHRBPDE4DMAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11667606-B2 | Thyromimetics | AUTOBAHN THERAPEUTICS, INC. (US) | 2023-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11667606-B2 | Thyromimetics | TPO, TSHR, TTR | THRA 4/4885THRB 9/4885PDE4D 1606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.